Orba Healthcare Holdings Co., Ltd. 2026 June Term Financial Summary

Business performance overview

Consolidated net sales for the 2026 June term reached 126,595 million yen, up 3.2% year on year. On the other hand, operating income declined to 1,679 million yen (down 15.2%), and net income attributable to owners of the parent declined to 1,112 million yen (down 22.2%). Details of sales and profits by segment (medical devices, SPD, and nursing care products) were disclosed. Amid ongoing price pass-through challenges due to rising prices and procurement costs, cost increases also impacted results. The financial summary has been revised, and revised figures have been disclosed. After the merger, maximizing the integration effects to achieve Vision2030 is a key point.

Future strategy and integration

With the merger with DIX effective September 1, 2026, the next corporate group-wide outlook will be disclosed once confirmed. Post-integration, the company plans to establish a position of 'comprehensive × specialized' as a medical device distributor by expanding the sales network, creating scale benefits, expanding routes for in-house planned products, optimizing logistics and IT investments, and strengthening human resources development. The dividend policy will prioritize retained earnings, with an expected year-end dividend of 80 yen; however, the post-merger outlook is currently undecided ahead of confirmation.